Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Wolfe Research downgraded INSM to Peer Perform from Outperform on Monday morning. The move came on the same day short interest jumped 26.5% in a single session to 6.46% of free float. Yet the options market told a different story: the put-call ratio fell to 0.54, 2.1 standard deviations below its 20-day mean, the most call-skewed reading in weeks.
Three distinct signals, pointing in opposite directions, landed on the same ticker within hours.
Andy Chen at Wolfe dropped his rating this morning, removing the Outperform that had sat on the stock. No new price target was published. The timing is notable. HC Wainwright's Andrew Fein reiterated Buy and announced a $220 target on the same morning. Barclays cut its target to $207 from $237 on September 30. Goldman Sachs reinstated with Buy and a $188 target on September 24.
The consensus is still constructive. Most covering analysts carry Buy-equivalent ratings with targets well above the current $100.60 close. But Wolfe's move reflects a stock down 9.5% over the past week and nearly 19.5% over the past month.
Earnings are scheduled for October 29. That is 17 days away. The last print on August 6 sent the stock up 32.4% in a single session.
Short interest hit 13.8 million shares on October 9. That is up 26.5% in one day and 26.6% over the week. At 6.46% of free float, the position is meaningful but not extreme.
The borrow market remains very loose. Availability stands at 5,637%, meaning shares to borrow vastly outnumber shares already borrowed. Cost to borrow is 0.41%, a low rate. Short sellers face no mechanical squeeze pressure from the lending side.
FINRA's fortnightly data puts days to cover at 6.5, a moderate figure.
The options market does not agree with the short sellers. The put-call ratio closed at 0.54 on October 9, against a 20-day mean of 0.68. That is a 2.1 standard deviation swing toward calls. The 52-week range on the PCR runs from 0.37 to 1.14, so the current reading sits toward the bullish end but is not a record.
Call buying into a 26% single-day short interest jump and a downgrade from a reputable firm is an unusual combination. One interpretation: options traders are positioning for an earnings bounce, given the stock's history of large post-earnings moves.
ORTEX forecasts a 45% probability that INSM is deleted from the CRSP US Large and CRSP US Mid indexes at the December 2026 Quarterly Review. The deletion line sits at $95.90. The stock closed at $100.60 on October 9, 4.7% above that threshold. If it falls through, index trackers would need to sell an estimated $277M combined across both indexes. The rank date is December 4.
Retail attention is also elevated. Wikipedia page views and ORTEX stock-page visits are running at a z-score of 2.41 against the company's own 90-day history.
See the live data behind this article on ORTEX.
Open INSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
